Assistant Professor of Practice
Assistant Director of Pharmacy Addictions Research & Medicine Program
Dr. Lindsey J. Loera graduated from the University of Texas at Austin College of Pharmacy (UTCOP) and completed a two-year postgraduate research and teaching fellowship with the Pharmacy Addictions Research & Medicine (PhARM) Program. She is now an Assistant Professor of Practice at the UTCOP and is the Assistant Director of the PhARM Program. In these roles, Dr. Loera conducts research that supports the Texas Targeted Opioid Response initiative and provides instruction in pharmacotherapy and interprofessional collaboration courses. In addition to these appointments, she serves as a faculty co-advisor to the UTCOP collegiate chapter of the American Association of Psychiatric Pharmacists (UT-AAPP).
Dr. Loera has been recognized with prestigious research awards from ACCP and AACP. She is a recipient of the 2020 UTCOP Pharmacy Mortar & Pestle Award, 2019 United States Public Health Service Excellence in Public Health Pharmacy Award, and the college's 2018 Benjamin Reed Leader in Pharmacy Award.
National Awards
American College of Clinical Pharmacy: Research Fellowship Best Poster (2021)
American Association of Colleges of Pharmacy: Finalist – Best Poster by a Resident, Fellow, or Postdoc (2021)
United States Excellence in Public Health Pharmacy Award (2019)
Local Awards
UT College of Pharmacy: Postdoctoral Program Abstract Winner (2021)
UT College of Pharmacy: Mortar & Pestle Award (2020)
UT College of Pharmacy: Benjamin Reed Leader in Pharmacy (2018)
Honors
Phi Lambda Sigma Pharmacy Leadership Society Inductee (2018)
Peer-Reviewed Journal Articles
*Zalmai RS, Hill LG, Loera LJ, Mosgrove Q, Brown CM. (2023). Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder. J Am Pharm Assoc. S1544-3191(23)00190-5. DOI: 10.1016/j.japh.2023.06.010.
Murchison ML, Loera LJ, *Hill LG. (2023). Medications for opioid use disorder in professional recovery programs in the U.S.: Policies and recommendation patterns. Ment Health Clin. 13(3):163-164. DOI: 10.9740/mhc.2023.06.163.
*Loera LJ, Hill LG, Evoy KE, Reveles KR. (2023). Research and scholarly methods: Audit studies. J Am Coll Clin Pharm. DOI: 10.1002/jac5.1782.
Britton TR, Clague MR, Zagorski CM, Hill LG, Loera LJ. A wound care and immunization needs assessment for clients of a mobile syringe services program in Austin, Texas. J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.10.018
Cance JD, Bingaman A, Kane H, Hairgrove S, Torrez SB, Buck A, Zagorski CM, Loera LJ, Hill LG. A qualitative exploration of unintentional vs. intentional exposure to fentanyl among people who use drugs in Austin, Texas. J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.10.005
Hill LG, Loera LJ, Torrez SB, Puzantian T, Ventricelli DJ, Eukel H, Peckham AM, Evoy KE, Chen C, Ganetsky V, Yeung M, Zagorski CM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in eleven U.S. states. Drug Alcohol Depend. 2022;237:109518. DOI: 10.1016/j.drugalcdep.2022.109518
Loera LJ*, Hill LG, Zagorski CM, Jermain ML, Tirado CF. Description and evaluation of a pilot advanced pharmacy practice experience in addiction medicine. Am J Pharm Educ. 8926. DOI: 10.5688/ajpe8926
White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ. Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review. Subst Abus. 2022;43(1):749-755. DOI: 10.1080/08897077.2021.2010161
Hill LG, Zagorski CM, Loera LJ. Increasingly powerful opioid antagonists are not necessary. Int J Drug Policy. 99:103457. DOI: 10.1016/j.drugpo.2021.103457
Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 116(6):1505-1511. DOI: 10.1111/ADD.15314
Renfro ML, Loera LJ, Tirado CF, Hill LG. Lofexidine for acute opioid withdrawal: A clinical case series. Ment Health Clin. 10(5):259-63. DOI: 10.9740/mhc.2020.09.259
Other Publications
Yeung MS, Johnston KE, Murchison ML, Loera LJ, Hill LG. (2022). Pharmacists: The most accessible healthcare provider, unless you have a substance use disorder. Pulses.
Loera LJ. (2022). Gaps in pharmacy support for people with opioid use disorder: An opportunity for advocacy. Texas Pharmacy Winter Magazine.
Required Didactic Courses:
- PHM 191U Foundations of Interprofessional Collaborative Practice I (P1)
- PHM 182V Pharmacy Practice Lab II (P1)
- PHM 193U and 193V Foundations of Interprofessional Collaborative Practice V and VI (P3)
- PHM 186V Pharmacy Practice Lab VI (P3)
- PHM 291 Pharmacotherapy of Pain and Addiction (P3)
Elective Coursework:
- PHM 693E Addiction Medicine Elective APPE (P4)
Online Continuing Education & Podcasts
Bratberg JP, Loera LJ, Hill LG. Barriers to treatment for opioid use disorder: Why aren’t pharmacists stocking buprenorphine? Association for Multidisciplinary Education and Research in Substance Use and Addiction. September 2021.
Loera LJ. Buprenorphine-naloxone versus extended-release naltrexone: A comparison of efficacy and safety. Texas Opioid Training Initiative. June 2021.
Hill LG, Loera LJ, Renfro ML, Madni N, Nguyen N. The story of the opioid crisis. The Healthcare Scholar Audio Experience. October 2019.
Television, Radio, & Print Mentions
KXAN Texas News – Mandatory checking of Texas prescription monitoring program delayed. July 31, 2019.
The Daily Texan: Student committee’s Prescription Drug Take Back Day combats nation-wide drug crisis. April 25, 2018.
Email address:
Phone:
Campus location:
US Mail Address:
The University of Texas at Austin
PHR 2.222G
2409 University Avenue, A1910
Austin, TX 78712